Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Real-World Evidence from the TriNetX Network: Assessing Immunotherapy's Impact on Second Primary Cancer Risk in Metastatic Lung Cancer
ABSTRACT
Background:
Lung cancer survivors are at high risk of developing a second primary cancer (SPC). This study investigated the impact of immune checkpoint inhibitors (ICIs) on the risk to develop a SPC in a large cohort of metastatic lung cancer patients.
Objective:
This study investigated the impact of immune checkpoint inhibitors (ICIs) on the risk to develop a SPC in a large cohort of metastatic lung cancer patients.
Methods:
Using a retrospective cohort from the TriNetX Global Collaborative research network, the study analyzed the incidence of SPC in metastatic lung cancer (MLC) patients treated with ICIs against those who were not. Propensity score matching and Kaplan-Meier to assess the effect of ICIs on the development of SPCs.
Results:
The study analyzed 2,844 MLC patients, with 685 receiving ICIs and 2,157 not receiving ICIs. Post-propensity score matching, each cohort included 685 patients. The 5-year analysis revealed a lower incidence of SPCs in the ICI group (1.5%) compared to the non-ICI group (4.2%), with a Hazard Ratio (HR) of 0.49 (95%CI [0.24-1.01]) indicating a reduced risk. Treatment with ICIs was associated with a significant risk reduction of SPC or death (HR=0.78; 95%CI [0.62-0.89]).
Conclusions:
ICIs reduce the risk of SPCs in metastatic lung cancer patients. Despite limitations, the study confirms the preventive role of ICIs and the importance of real-world data to identify novel paradigm changing strategies. Clinical Trial: Not applicable
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.